Oncology Today with Dr Neil Love
Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.
Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application.
CME information and select publications
HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy
Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, and Dr Virginia Kaklamani from the UT Health San Antonio MD Anderson Cancer Center in San Antonio, Texas, discuss patient cases and review relevant data on the management of ER-positive, HER2-negative metastatic breast cancer.
CME information and select publications
Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the management of SCLC.
CME information and select publications
Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.
CME information and select publications
Antibody-Drug Conjugates in Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
Prof Ramez N Eskander from UC San Diego Moores Cancer Center in California, Dr Bradley J Monk from Florida Cancer Specialists & Research Institute in West Palm Beach and Dr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, review the treatment landscape of antibody-drug conjugate–directed therapy for gynecologic cancers and review recently presented clinical findings from the SGO 2026 Annual Meeting on Women’s Cancer.
CME information and select publications
Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper
Prof Bernd Kasper from the Mannheim Cancer Center in Mannheim, Germany, discusses recent updates on available and novel treatment strategies for desmoid tumors.
CME information and select publications here.
Colorectal Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Arvind Dasari from the University of Texas MD Anderson Cancer Center in Houston and Dr Anwaar Saeed from UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, discuss key clinical trial data regarding the management of colorectal cancer.
CME information and select publications here.
Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.
CME information and select publications here.
Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.
CME information and select publications here.
Ovarian Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer
Prof Nicoletta Colombo from the European Institute of Oncology IRCCS in Milan, Italy, Dr Alexander Olawaiye from the University of Pittsburgh School of Medicine in Pennsylvania, Dr Gottfried Konecny from the University of California, Los Angeles and Dr Shannon Westin from the MD Anderson Cancer Center in Houston, Texas, discuss key clinical trial data surrounding the management of ovarian cancer, alongside clinical cases and questions.
CME information and select publications here.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Jaffer A Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel J Klempner from Massachusetts General Hospital in Boston review data supporting immunotherapy for gastroesophageal cancers and findings presented at the 2026 ASCO Gastrointestinal Cancers Symposium.
CME information and select publications here.
PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida
Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer.
CME information and select publications here.
Immunotherapy for Endometrial Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancer
Dr Floor J Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, and Dr Ritu Salani from the David Geffen School of Medicine at UCLA in Los Angeles, California, discuss key clinical trial data, clinical cases and questions surrounding the management of endometrial cancer using immunotherapy.
CME information and select publications here.
Oncology Nursing Update: Nonmelanoma Skin Cancers — An Interview with Dr Nikhil Khushalani
Dr Nikhil I Khushalani from the Moffitt Cancer Center in Tampa, Florida, discusses available and novel treatment strategies for nonmelanoma skin cancers.
NCPD information and select publications here.
Localized Colorectal Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.
CME information and select publications here.
Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Aditya Bardia from the University of California Los Angeles and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the use of oral SERDs in the management of breast cancer.
CME information and select publications here.
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported over the past year.
CME information and select publications here.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.
CME information and select publications here.
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Andrew J Armstrong from the Duke Cancer Institute in Durham, North Carolina, and Dr Scott T Tagawa from Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss the selection and sequencing of therapy for patients with prostate cancer and summarize major advances in the treatment landscape over the past year.
CME information and select publications here.
Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.
CME information and select publications here.
Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer.
CME information and select publications here.
HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making
Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer.
CME information and select publications here.
Metastatic Bladder Cancer — Rapid Case Review Issue 4
Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia, and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston.
CME information and select publications here.
ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer.
CME information and select publications here.
Localized Colorectal Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.
CME information and select publications here.
CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.
CME information and select publications here.
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.
CME information and select publications here.
Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan
Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.
CME information and select publications here.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.
CME information and select publications here.
Nonmelanoma Skin Cancers — A Roundtable Discussion on the Multidisciplinary Management of Cutaneous Squamous Cell and Basal Cell Carcinomas
Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida, Dr Soo J Park from the UC San Diego Moores Cancer Center in California, Dr Vishal Anil Patel from the GW Cancer Center in Washington, DC, and Dr Evan Wuthrick, also from Moffitt Cancer Center, discusses recent updates on available and novel treatment strategies for nonmelanoma skin cancers.
CME information and select publications here.
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.
CME information and select publications here.
AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer.
CME information and select publications here.
Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway
Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors.
CME information and select publications here.
Metastatic Bladder Cancer — Rapid Case Review Issue 3
Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston.
CME information and select publications here.
Localized Colorectal Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.
CME information and select publications here.
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic’s Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management.
CME information and select publications here.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.
CME information and select publications here.
CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.
CME information and select publications here.
Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.
CME information and select publications here.
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.
CME information and select publications here.
